Literature DB >> 12207642

The significance of QT interval in drug development.

Rashmi R Shah1.   

Abstract

Mesh：

Year:  2002        PMID： 12207642      PMCID： PMC1874403          DOI： 10.1046/j.1365-2125.2002.01627.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  79 in total

Review 1.  The assessment of potential for QT interval prolongation with new pharmaceuticals: impact on drug development.

Authors:  M R Gralinski
Journal:  J Pharmacol Toxicol Methods       Date:  2000 Mar-Apr       Impact factor: 1.950

Review 2.  Assessment of QTc prolongation for non-cardiac-related drugs from a drug development perspective.

Authors:  P L Bonate; T Russell
Journal:  J Clin Pharmacol       Date:  1999-04       Impact factor: 3.126

3.  Pharmacokinetics of sertindole and dehydrosertindole in volunteers with normal or impaired renal function.

Authors:  S L Wong; S Menacherry; D Mulford; P J Schmitz; C Locke; G R Granneman
Journal:  Eur J Clin Pharmacol       Date:  1997       Impact factor: 2.953

4.  QT interval prolongation as predictor of sudden death in patients with myocardial infarction.

Authors:  P J Schwartz; S Wolf
Journal:  Circulation       Date:  1978-06       Impact factor: 29.690

Review 5.  The pre-clinical assessment of QT interval prolongation: a comparison of in vitro and in vivo methods.

Authors:  A S Davis
Journal:  Hum Exp Toxicol       Date:  1998-12       Impact factor: 2.903

6.  Torsade de pointes due to quinidine: observations in 31 patients.

Authors:  J L Bauman; R A Bauernfeind; J V Hoff; B Strasberg; S Swiryn; K M Rosen
Journal:  Am Heart J       Date:  1984-03       Impact factor: 4.749

7.  Mechanism of the cardiotoxic actions of terfenadine.

Authors:  R L Woosley; Y Chen; J P Freiman; R A Gillis
Journal:  JAMA       Date:  1993 Mar 24-31       Impact factor: 56.272

8.  [Torsades de pointe. Apropos of 60 cases].

Authors:  P Salle; J L Rey; P Bernasconi; J C Quiret; M Lombaert
Journal:  Ann Cardiol Angeiol (Paris)       Date:  1985-06

Review 9.  Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group.

Authors:  P Jaillon; J Morganroth; I Brumpt; G Talbot
Journal:  J Antimicrob Chemother       Date:  1996-05       Impact factor: 5.790

Review 10.  Human ether-a-gogo related gene (HERG) K+ channels as pharmacological targets: present and future implications.

Authors:  M Taglialatela; P Castaldo; A Pannaccione; G Giorgio; L Annunziato
Journal:  Biochem Pharmacol       Date:  1998-06-01       Impact factor: 5.858
View more
  51 in total

1.  A pharmacokinetic and safety study of single dose intravenous combretastatin A4 phosphate in Chinese patients with refractory solid tumours.

Authors:  Xuexin He; Su Li; He Huang; Zhiming Li; Likun Chen; Sheng Ye; Jiajia Huang; Jing Zhan; Tongyu Lin
Journal:  Br J Clin Pharmacol       Date:  2011-06       Impact factor: 4.335

2.  Comparing methods of measurement for detecting drug-induced changes in the QT interval: implications for thoroughly conducted ECG studies.

Authors:  Nkechi E Azie; Gregory Adams; Borje Darpo; Steven F Francom; Emery C Polasek; Joy M Wisser; Joseph C Fleishaker
Journal:  Ann Noninvasive Electrocardiol       Date:  2004-04       Impact factor: 1.468

3.  Cardiac safety, drug-induced QT prolongation and torsade de pointes (TdP).

Authors:  James M Ritter
Journal:  Br J Clin Pharmacol       Date:  2012-03       Impact factor: 4.335

Review 4.  Drugs, QT interval prolongation and ICH E14: the need to get it right.

Authors:  Rashmi R Shah
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

Review 5.  Drugs, QTc interval prolongation and final ICH E14 guideline : an important milestone with challenges ahead.

Authors:  Rashmi R Shah
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

Review 6.  Pharmacogenetics in drug regulation: promise, potential and pitfalls.

Authors:  Rashmi R Shah
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2005-08-29       Impact factor: 6.237

7.  The effect of therapeutic and supratherapeutic oral doses of nomegestrol acetate (NOMAC)/17β-estradiol (E2) on QTcF intervals in healthy women: results from a randomized, double-blind, placebo- and positive-controlled trial.

Authors:  Pieter-Jan de Kam; Jacqueline van Kuijk; Otilia Lillin; Teun Post; Torben Thomsen
Journal:  Clin Drug Investig       Date:  2014-06       Impact factor: 2.859

Review 8.  Opioids and Cardiac Arrhythmia: A Literature Review.

Authors:  Mina Behzadi; Siyavash Joukar; Ahmad Beik
Journal:  Med Princ Pract       Date:  2018-08-02       Impact factor: 1.927

9.  Co-administration of ketoconazole with H1-antagonists ebastine and loratadine in healthy subjects: pharmacokinetic and pharmacodynamic effects.

Authors:  P Chaikin; M S Gillen; M Malik; H Pentikis; G R Rhodes; D J Roberts
Journal:  Br J Clin Pharmacol       Date:  2005-03       Impact factor: 4.335

10.  Effect of selection of QTc formula on eligibility of cancer patients for phase I clinical trials.

Authors:  Mitesh J Borad; Arundhati D Soman; Martin Benjamin; Daniel Casa; Waibhav D Tembe; Barbara F Piper; Ramesh Ramanathan; Raoul Tibes; Gayle Jameson; Karen Ansaldo; Daniel D Von Hoff
Journal:  Invest New Drugs       Date:  2012-12-16       Impact factor: 3.850
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.